RXST — RxSight, Inc.

Nasdaq · Unknown · Unknown · CIK 1111485 ·
Last close
$5.99
Market Cap
$247.97M
52W High
$8.08
52W Low
$5.30
ADV30
690,791
Next earnings
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 30,893,000 23,498,000 -17,829,000 -15,884,000 303,993,000 17,573,000 36,698,000
Dec 2025 32,608,000 25,263,000 -11,337,000 -9,152,000 311,814,000 19,949,000 36,131,000
Sep 2025 30,340,000 24,227,000 -12,178,000 -9,816,000 308,533,000 29,633,000 32,563,000
Jun 2025 33,637,000 25,190,000 -14,003,000 -11,786,000 309,009,000 40,355,000 30,997,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,511,000
Investing CF
$16,889,000
Financing CF
$1,863,000
CapEx
$-3,830,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.95
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-661,039,000
Inventory
$31,559,000
Receivables
$23,383,000
ST Investments
$208,179,000
EBIT TTM
$-38,859,000
Pretax Income TTM
$-38,879,000
Interest Exp TTM
$20,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$127,477,000
EBITDA
$-52,022,000
Free Cash Flow
$-969,250
Enterprise Value
$40,911,688
Total Cash
$217,880,000
Total Debt
$10,826,000
Shares Out
41,396,609
Trailing EPS
$-1.13
Book Value
$6.68
ROE
-17.1%
ROA
-11.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 134,479,000 -48,191,000 -38,944,000 311,814,000 36,131,000 -15,511,000
Dec 2024 139,927,000 -36,858,000 -27,455,000 318,563,000 37,325,000 -16,946,000
Dec 2023 89,077,000 -50,085,000 -48,608,000 182,550,000 22,188,000 -41,593,000
Dec 2022 49,005,000 -63,318,000 -66,756,000 150,164,000 60,262,000 -58,850,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.56

News headlines (Yahoo Finance, 1h cache)

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
2026-05-19 20:10 · Yahoo
RxSight (RXST) Q1 2026 Earnings Transcript
2026-05-12 16:04 · Yahoo
RxSight, Inc. Q1 2026 Earnings Call Summary
2026-05-07 12:30 · Yahoo
RxSight Q1 Earnings Call Highlights
2026-05-07 05:12 · Yahoo
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
2026-05-06 22:30 · Yahoo
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
2026-05-06 20:05 · Yahoo
How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets
2026-05-04 04:31 · Yahoo
RxSight, Inc. to Present at the Bank of America Healthcare Conference
2026-04-29 20:10 · Yahoo
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
2026-04-22 20:10 · Yahoo
How The RxSight (RXST) Story Is Shifting With New Guidance And Street Price Targets
2026-04-19 08:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.